SUBSCRIBE
SUBSCRIBE

Hayley Shasteen

Courtesy of Michael Vi/Getty Images
Drug Development
Following Q1 Assessment, Allogene Remains Focused on CAR-T Therapy
After the market closed on Wednesday, Allogene reported its first-quarter financial results, along with updates to its research programs. The report marked Allogene’s fourth anniversary.
May 4, 2022
 · 
2 min read
 · 
Hayley Shasteen
Courtesy of Alexanderstock23/Shutterstock
Drug Development
Compass, Astrazeneca Move Forward in Biliary Tract Cancer Treatments
Compass and AstraZeneca have both provided updates to their clinical therapeutic programs focused on biliary tract cancers.
May 4, 2022
 · 
2 min read
 · 
Hayley Shasteen
Maddie Meyer/Getty Images
Drug Development
Moderna Highlights More than $6B in Revenue, Talks Boosters
Moderna held its 2022 Q1 earnings call this morning announcing $6.1 billion in revenue and robust plans to roll out COVID-19 boosters this fall.
May 4, 2022
 · 
2 min read
 · 
Hayley Shasteen
Courtesy of Getty Images
Business
Genesis and Lilly Ink AI Collab Worth Up to $670M
Genesis Therapeutics and Eli Lilly have entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.
May 3, 2022
 · 
2 min read
 · 
Hayley Shasteen
Courtesy of Getty Images
Business
Dianthus Debuts with $100M and a Mission to Make Autoimmunity Less Inconvenient
Dianthus Therapeutics launched today with $100 million in Series A financing led by 5AM Ventures, Avidity Partners and Fidelity Research and Management. The company plans to tackle severe and rare autoimmune diseases by utilizing antibodies that target complements.
May 3, 2022
 · 
3 min read
 · 
Hayley Shasteen
Courtesy of Clinical Photography/Science Photo Lib
FDA
Orphalan Touts First FDA-Approved Wilson’s Disease Treatment Since 1970
Orphalan announced the FDA has granted full approval to Cuvrior (trientine tetrahydrochloride) for the treatment of Wilson’s Disease, a rare genetic disorder.
May 2, 2022
 · 
2 min read
 · 
Hayley Shasteen
Elderly man examined by an ophthalmologist
Drug Development
Positive Blepharitis Data in Hand, Tarsus Gears Up for FDA Submission (Updated)
Tarsus announced positive topline data from its Phase III clinical trial of TP-03 Demodex blepharitis, along with the commencement of an underwritten public offering of $50 million of shares of its common stock.
May 2, 2022
 · 
2 min read
 · 
Hayley Shasteen
Job Trends
Pharma Expansions: Beigene, Boehringer Ingelheim to Break Ground for New Facilities
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
April 29, 2022
 · 
4 min read
 · 
Hayley Shasteen
Aryballe President Terri Jordan/Aryballe
The Doctor Will Smell You Now: The Rise of AI-Olfaction in Healthcare
Researchers from Zhejiang University in China developed an artificially intelligent olfactory system for the diagnosis of Parkinson’s disease. An “e-nose” was built to “smell” samples from patients.
April 28, 2022
 · 
5 min read
 · 
Hayley Shasteen
Merck Makes Waves in Q1 with COVID-19 Treatment, Cancer Portfolio
Merck held a conference call Thursday morning to discuss its Q1 2022 earnings. The company reported a 50% growth in revenue, increasing its worldwide sales to $15.9 billion.
April 28, 2022
 · 
2 min read
 · 
Hayley Shasteen
Courtesy of JHVEPhoto/Getty Images
Business
It’s Pfizer to the Rescue After Zentalis’ Shares Stumble at AACR
Zentalis Pharmaceuticals announced that Pfizer made a $25 million equity investment in the company.
April 27, 2022
 · 
3 min read
 · 
Hayley Shasteen
In Control Room Doctor and Radiologist Discuss Diagnosis while Watching Procedure and Monitors Showing Brain Scans Results, In the Background Patient Undergoes MRI or CT Scan Procedure.
Drug Development
Study Suggests Late Stage Asset Lecanemab Could Delay Progression of Alzheimer’s Dementia
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
April 27, 2022
 · 
2 min read
 · 
Hayley Shasteen
Low wide-angle view looking up to modern skyscrapers in business district on a beautiful sunny day with blue sky and clouds
Drug Development
Pheast Garners $76M to Launch Therapy Targeting Elusive Cancer Protein
Pheast Therapeutics launched today with $76 million in Series A financing. Pheast is focused on developing cancer checkpoint therapies to fight malignant cells, focusing on ovarian and breast cancers.
April 26, 2022
 · 
2 min read
 · 
Hayley Shasteen
Policy
Is the US Running Blind Toward COVID-19 Boosters?
How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.
April 26, 2022
 · 
2 min read
 · 
Hayley Shasteen
Pierre Suu/Getty Images
Business
Pfizer, Valneva Lyme Vaccine Shows Promise in Pediatric Patients
Pfizer and its partner, Valneva, have announced positive Phase II data from its trial of vaccine candidate VLA15 in a pediatric population. VLA15 is intended to prevent Lyme Disease (LD).
April 26, 2022
 · 
2 min read
 · 
Hayley Shasteen
Load More